Loading...
XASX
PER
Market cap33mUSD
Jan 29, Last price  
0.06AUD
Name

Antisense Therapeutics Ltd

Chart & Performance

D1W1MN
XASX:PER chart
P/E
—
P/S
31.96
EPS
—
Div Yield, %
—
Shrs. gr., 5y
26.65%
Rev. gr., 5y
-55.61%
Revenues
2m
-11.14%
000762,3686,399,0000000003,863,9881,000,00069,1150586,788668,433577,7641,777,9041,579,849
Net income
-11m
L+95.06%
-4,609,624-6,265,839-5,462,401-4,835,963-2,136,886-2,649,727-3,424,875-1,813,550-1,801,278-2,454,842-3,013,272706,918-2,514,443-2,754,799-2,331,015-2,305,862-5,890,210-8,067,192-5,834,080-11,379,828
CFO
-8m
L+4.44%
-2,209,608-5,585,305-3,958,499-2,679,528-3,401,498-3,283,821-1,336,627-1,867,239-2,405,200-2,833,186-3,107,8861,268,875-2,025,026-2,914,2220-2,928,436-3,945,358-5,834,156-7,805,166-8,151,329

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia.
URL
https://www.antisense.com.au/
IPO date
Dec 20, 2001
Employees
8
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT